United Therapeutics (UTHR) Interest Expenses (2009 - 2026)

United Therapeutics (UTHR) has 18 years of Interest Expenses data on file, last reported at $1.8 billion in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses rose 104.29% year-over-year to $1.8 billion; the trailing twelve-month figure through Mar 2026 stood at $1.8 billion (up 104.29% YoY), and the FY2025 full-year result was $19.5 million, down 54.55% from the prior year.
• Interest Expenses advanced to $1.8 billion in Q1 2026, from $3.1 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $1.8 billion in Q1 2026 to a low of $3.1 million in Q4 2025.
• A 5-year average of $646.7 million and a median of $576.5 million in 2023 frame the typical range for Interest Expenses.
• Across the five-year window, Interest Expenses surged 161.7% in 2022 and slumped 65.56% in 2024, its largest moves.
• Tracing UTHR's Interest Expenses over 5 years: stood at $12.3 million in 2022, then gained by 22.76% to $15.1 million in 2023, then tumbled by 65.56% to $5.2 million in 2024, then tumbled by 40.38% to $3.1 million in 2025, then soared by 57003.23% to $1.8 billion in 2026.
• Business Quant data shows UTHR's Interest Expenses at $1.8 billion in Q1 2026, $3.1 million in Q4 2025, and $1.4 billion in Q3 2025.